Targeting the renin-angiotensin system to improve cancer treatment: Implications for immunotherapy.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 28978752.
- Also identified by DOI 10.1126/scitranslmed.aan5616 and PMC identifier 5928511.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
Renin-angiotensin system (RAS) inhibitors (RASi)-widely prescribed for the treatment of cardiovascular diseases-have considerable potential in oncology. The RAS plays a crucial role in cancer biology and affects tumor growth and dissemination directly and indirectly by remodeling the tumor microenvironment. We review clinical data on the benefit of RASi in primary and metastatic tumors and propose that, by activating immunostimulatory pathways, these inhibitors can enhance immunotherapy of cancer.
Medical subject headings
- Immunotherapy
- Neoplasms
- Renin-Angiotensin System